Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Gliomas are the most common malignant brain tumors in adults, characterized by a high proliferation and invasion. The tumor microenvironment is rich in growth-promoting signals and immunomodulatory pathways, which increase the tumor’s aggressiveness. In response to hypoxia and glioma therapy, the amounts of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) strongly increase in the extracellular space, and the purinergic signaling is triggered by nucleotides’ interaction in P2 receptors. Several cell types are present in the tumor microenvironment and can facilitate tumor growth. In fact, tumor cells can activate platelets by the ADP-P2Y12 engagement, which plays an essential role in the cancer context, protecting tumors from the immune attack and providing molecules that contribute to the growth and maintenance of a rich environment to sustain the protumor cycle. Besides platelets, the P2Y12 receptor is expressed by some tumors, such as renal carcinoma, colon carcinoma, and gliomas, being related to tumor progression. In this context, this review aims to depict the glioma microenvironment, focusing on the relationship between platelets and tumor malignancy.

Details

Title
P2Y12 Purinergic Receptor and Brain Tumors: Implications on Glioma Microenvironment
Author
Fernanda Bueno Morrone 1   VIAFID ORCID Logo  ; Vargas, Pedro 2 ; Rockenbach, Liliana 2   VIAFID ORCID Logo  ; Thamiris Becker Scheffel 3 

 Laboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, PUCRS, Porto Alegre 90610-001, RS, Brazil; [email protected] (P.V.); [email protected] (L.R.); [email protected] (T.B.S.); Programa de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Porto Alegre 90610-001, RS, Brazil; Programa de Pós-Graduação em Medicina e Ciências da Saúde, PUCRS, Porto Alegre 90610-001, RS, Brazil 
 Laboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, PUCRS, Porto Alegre 90610-001, RS, Brazil; [email protected] (P.V.); [email protected] (L.R.); [email protected] (T.B.S.); Programa de Pós-Graduação em Medicina e Ciências da Saúde, PUCRS, Porto Alegre 90610-001, RS, Brazil 
 Laboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, PUCRS, Porto Alegre 90610-001, RS, Brazil; [email protected] (P.V.); [email protected] (L.R.); [email protected] (T.B.S.); Programa de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Porto Alegre 90610-001, RS, Brazil 
First page
6146
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
14203049
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2584467201
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.